Tesamorelin: Approved Drug, Sold Peptide

What is tesamorelin approved for, and on what evidence?

Tesamorelin is an unusual molecule in this index, because most of the compounds recorded here are asked whether any human evidence exists at all. This one has a registrational file. It has been an approved drug in the United States since November 2010, and in March 2025 the FDA approved EGRIFTA WR, a concentrated formulation reconstituted weekly rather than daily ^[3].

The approval is narrow, and the narrowness is the whole point. It covers the reduction of excess abdominal fat in adults with HIV who have lipodystrophy, and nothing else. The pivotal trial randomized 404 patients to tesamorelin 2 mg daily or placebo; visceral adipose tissue fell 10.9 percent against 0.6 percent with placebo over six months, reaching approximately 18 percent in patients who continued for a full year ^[1]. A pooled analysis of the two phase 3 studies reports the same population and the same endpoint ^[2].

An indication is not a description of a drug's effects; it is a description of the population and endpoint in which those effects were demonstrated. Everything below follows from holding that distinction rather than relaxing it.

What does the trial literature outside HIV actually contain?

Searched across the three names the compound is indexed under in August 2026, the literature runs to 127 records, of which 28 carry the clinical-trial publication type and 26 the stricter randomized-controlled-trial type. Of those 28, 21 name HIV or lipodystrophy ^[7].

The remaining seven were read individually rather than counted, because a count of trials is not a finding about what was tested. One is a trial of a different growth hormone product in which tesamorelin appears incidentally. The rest measure cognition in adults with mild cognitive impairment and in healthy older adults ^[6], glycemic safety in patients with type 2 diabetes ^[5], mitochondrial recovery, and a hormone-secretion relationship ^[7].

One of the seven is a controlled trial of body composition, and it is the one a reader asking about fat loss needs. It is examined in the next section. The point of the census is what surrounds it: a molecule marketed for general fat reduction has, after sixteen years on the market, a single randomized body-composition trial conducted outside the population it was approved for.

Why does visceral fat not mean general fat loss?

That trial randomized 60 abdominally obese adults without HIV to tesamorelin 2 mg daily or placebo for twelve months. The subjects were not healthy volunteers; they were selected for reduced growth hormone secretion, which is the same deficit the approved indication describes in a different patient group.

Visceral adipose tissue fell by 35 square centimeters against placebo, with a 95 percent confidence interval of −58 to −12 and p equal to 0.003. Abdominal subcutaneous adipose tissue did not change significantly: a treatment effect of −10 square centimeters, a confidence interval of −32 to +13, and p equal to 0.40 ^[4].

Those two results are the whole answer, and they point in opposite directions for the reader who arrived here. Visceral fat is the deep abdominal compartment that surrounds the organs; subcutaneous fat is the layer beneath the skin, and it is the compartment a person sees, measures with a tape, and means when the phrase is general fat loss. The trial moved the first and left the second where it found it, in a population already selected for a hormone deficit. A drug that selectively reduces one compartment in deficient patients is not a drug shown to reduce body fat in people generally, and the trial's own authors describe the effect as selective ^[4].

What is sold under the name, and is it the approved product?

The approved product is the lawful supply route, and it is a prescription drug dispensed against a diagnosis. Tesamorelin has no compounding route at all: its application was deemed a biologics license on March 23, 2020 ^[8], and FDA's notice to compounders states that biological products which transitioned that day are not eligible for the compounding exemptions under section 503A or 503B ^[9]. The monograph records that posture with the date it was verified, and the approved hub records the small set of peptides that share it.

Material offered under the molecule's name outside that route is not the approved product and does not inherit its evidence. It is research-use-only chemical supply, sold outside pharmacy licensure and prescriber oversight, and the trial results above attach to a manufactured drug administered at a stated dose under a protocol, not to the contents of an unlabeled vial. The research-use-only entry sets out what that labeling posture does and does not mean.

The gap that produces the question is a real one: a compound with 70,000 United States searches a month, a real approval, a real evidence base, and an indication that fits almost none of the people searching for it. A contrasting case is BPC-157, which shares the commercial visibility and has no human trial record at all.

Elsewhere in this index